论文部分内容阅读
Extended adjuvant endocrine therapy (10 vs.5 years) trials have demonstrated improved outcomes in early-stage estrogen receptor (ER)-positive breast cancer;however,the absolute benefit is modest,and toxicity and tolerability challenges remain.